Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Lilly sues online vendors, medical spa
Lilly's weight loss drug shortage deemed over, but hurdles remain
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
Lilly sues online vendors, medical spa over copycat weight-loss drugs
Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, including in the form of dissolvable tablets.
Eli Lilly sues over knockoffs of signature weight loss drug, Zepbound
Eli Lilly sued three medical spas and online vendors for selling products that claim to contain the ingredient in its weight-loss medicine Zepbound.
Mangoceuticals To Defend Against Eli Lilly's Lawsuit Over Alleged Copying Of Weight-Loss Drugs
Mangoceuticals Inc. (MGRX) announced that Eli Lilly has made public allegations and filed a lawsuit against the company, claiming
Mangoceuticals refutes claims made by Lilly in weight-loss drug lawsuit
Mangoceuticals (MGRX) said it strongly refutes claims made in a lawsuit filed by Eli Lilly (LLY) over a compounded version of Lilly’s weight-loss drug tirzepatide. Read more here.
41m
on MSN
UK approves Lilly's Alzheimer's drug, but deemed 'too expensive' for wide use
Eli Lilly's treatment for early Alzheimer's was deemed too expensive for wide use by UK's cost-effectiveness body on ...
pharmaphorum
3h
Lawmakers seek answers on Pfizer, Lilly telehealth moves
Discussing Pfizer's platform, the lawmakers write that it "creates the impression that any patient interested in a particular ...
3h
Eli Lilly Alzheimer’s Drug Rejected for NHS Use in England
Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the ...
15h
on MSN
UK's NHS to block Eli Lilly's Alzheimer's drug on Wednesday, Telegraph reports
Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too ...
pharmaphorum
2h
Lilly's Alzheimer's drug gets UK nod but won't be NHS-funded
The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to ...
FiercePharma
17h
Senators probe whether Pfizer, Lilly DTC platforms create 'potential for inappropriate prescribing'
A group of U.S. senators are digging into the direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer this ...
STAT
22h
Pharmalittle: We’re reading about a probe of Pfizer and Lilly telehealth, pharma exec donations, and more
Dick Durbin (D-Ill.) demanded answers from Pfizer and Eli Lilly about their relationships with the telehealth prescribers ...
WJCL on MSN
57m
Maggie Lilly causing a buzz with her 'Party of Hive' granola
Maggie Lilly is creating a buzz with her Party of Hive granola.
The News Leader (Staunton) on MSN
15h
Five Waynesboro residents ask judge to force Lilly and Mares to certify upcoming election
A counter lawsuit asking a judge to force two Waynesboro Board of Election members to certify the Nov. 5 election was filed ...
9h
Work by Slim Aarons, Lilly Pulitzer to open Ann Norton Sculpture Gardens' season
"Slim Aarons: Gold Coast" is organized by Shawn Waldron, the curator for Getty Images and manager of the Slim Aarons Archive ...
15h
Eli Lilly & Co. stock underperforms Tuesday when compared to competitors despite daily gains
Eli Lilly & Co. closed $63.38 below its 52-week high ($972.53), which the company reached on August 22nd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
New York Stock Exchange
United Kingdom
Food and Drug Administration
Pfizer
Alzheimer's disease
Feedback